FET-PET for Evaluation of Response of Recurrent GBM to Avastin

Summary

Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which we expect to obtain definitive results, and two secondary aims, under which we plan to generate preliminary data to support a future, larger project.

Timeline

Start

2013-02

Primary completion

2015-09-13

Completion

2015-09-13

Drugs

Indications